Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.02 - $3.23 $44,000 - $139,335
43,138 Added 20.52%
253,367 $319,000
Q4 2023

Feb 14, 2024

SELL
$1.72 - $3.18 $76,166 - $140,819
-44,283 Reduced 17.4%
210,229 $573,000
Q3 2023

Nov 14, 2023

BUY
$2.13 - $5.55 $30,218 - $78,737
14,187 Added 5.9%
254,512 $577,000
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $771,397 - $1.12 Million
214,277 Added 822.62%
240,325 $1.05 Million
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $112,006 - $215,416
26,048 New
26,048 $115,000
Q2 2022

Aug 15, 2022

SELL
$2.6 - $6.14 $272,222 - $642,864
-104,701 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$5.08 - $9.81 $3,942 - $7,612
776 Added 0.75%
104,701 $8.52 Million
Q4 2021

Feb 14, 2022

SELL
$8.55 - $111.89 $584,153 - $7.64 Million
-68,322 Reduced 39.67%
103,925 $8.45 Million
Q3 2021

Nov 12, 2021

SELL
$76.53 - $110.43 $397,802 - $574,015
-5,198 Reduced 2.93%
172,247 $18.2 Million
Q2 2021

Aug 16, 2021

BUY
$85.37 - $114.1 $3.6 Million - $4.81 Million
42,141 Added 31.15%
177,445 $15.1 Million
Q1 2021

May 17, 2021

BUY
$109.73 - $153.66 $3.52 Million - $4.93 Million
32,110 Added 31.12%
135,304 $15.5 Million
Q4 2020

Feb 16, 2021

BUY
$79.58 - $152.45 $432,994 - $829,480
5,441 Added 5.57%
103,194 $14.4 Million
Q3 2020

Nov 16, 2020

SELL
$66.43 - $90.99 $143,023 - $195,901
-2,153 Reduced 2.16%
97,753 $7.96 Million
Q2 2020

Aug 14, 2020

BUY
$44.04 - $80.69 $766,912 - $1.41 Million
17,414 Added 21.11%
99,906 $7.18 Million
Q1 2020

May 14, 2020

BUY
$44.49 - $93.39 $28,073 - $58,929
631 Added 0.77%
82,492 $3.67 Million
Q4 2019

Feb 14, 2020

BUY
$66.49 - $137.73 $342,157 - $708,758
5,146 Added 6.71%
81,861 $7.81 Million
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $152,644 - $441,830
4,924 Added 6.86%
76,715 $6.03 Million
Q2 2019

Aug 15, 2019

BUY
$36.0 - $44.73 $2.58 Million - $3.21 Million
71,791 New
71,791 $3.11 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $54.2M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.